Abstract:Background
We report the development of an efficient antibody delivery system for the incorporation of trastuzumab (TZ) into poly(lactic-
co
-glycolic) acid nanoparticles (PLGA NPs). The aim of the work was to overcome the current limitations in the clinical use of therapeutic antibodies, including immunogenicity, poor pharmacokinetics, low tumor penetration and safety issues.
Materials and methods
Trastuzumab-loaded PLGA NPs (PLGA-TZ) were sy… Show more
“…6,7 Moreover, PLGA-based nanocarriers have been used as drug delivery systems to administer proteins, 8,9 DNA 10 and anticancer drugs among others. 1,11,12 Nonetheless, despite their compositional similarities, any novel PLGA-based drug delivery system will require a thorough evaluation to address potential toxicity issues and study the pharmacokinetics and the pharmacodynamics of each specific carrier. Such preclinical in vitro and in vivo studies, comprising multiple biological characterization phases, could be expedited by endowing the carrier with complementary imaging capacities.…”
“…6,7 Moreover, PLGA-based nanocarriers have been used as drug delivery systems to administer proteins, 8,9 DNA 10 and anticancer drugs among others. 1,11,12 Nonetheless, despite their compositional similarities, any novel PLGA-based drug delivery system will require a thorough evaluation to address potential toxicity issues and study the pharmacokinetics and the pharmacodynamics of each specific carrier. Such preclinical in vitro and in vivo studies, comprising multiple biological characterization phases, could be expedited by endowing the carrier with complementary imaging capacities.…”
“… 28 Recently, various researchers have demonstrated the selective internalization of monoclonal antibody-modified nanoparticles in comparison to non-modified nanoparticles. 29 , 30 …”
Background
One major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-infrared laser light to enable local photo-thermal therapy and the release of chemotherapeutic agents, which could achieve combined therapeutic efficiency.
Methods
To exploit the magnetic potential of iron oxide, we prepared and characterized citric acid-coated iron oxide magnetic nanoparticles (CMNPs) and encapsulated them into thermo-sensitive liposomes (TSLs). The chemotherapeutic drug, doxorubicin (DOX), was then loaded into the CMNP-TSLs, which were coated with an antibody against the epidermal growth factor receptor (EGFR), cetuximab (CET), to target EGFR-expressing breast cancer cells in vitro and in vivo studies in mouse model.
Results
The resulting CET-DOX-CMNPāTSLs were stable with an average diameter of approximately 120 nm. First, the uptake of TSLs into breast cancer cells increased by the addition of the CET coating. Next, the viability of breast cancer cells treated with CET-CMNP-TSLs and CET-DOX-CMNP-TSLs was reduced by the addition of photo-thermal therapy using near-infrared (NIR) laser irradiation. What is more, the viability of breast cancer cells treated with CMNP-TSLs plus NIR was reduced by the addition of DOX to the CMNP-TSLs. Finally, photo-thermal therapy studies on tumor-bearing mice subjected to NIR laser irradiation showed that treatment with CMNP-TSLs or CET-CMNP-TSLs led to an increase in tumor surface temperature to 44.7Ā°C and 48.7Ā°C, respectively, compared with saline-treated mice body temperature ie, 35.2Ā°C. Further, the hemolysis study shows that these nanocarriers are safe for systemic delivery.
Conclusion
Our studies revealed that a combined therapy of photo-thermal therapy and targeted chemotherapy in thermo-sensitive nano-carriers represents a promising therapeutic strategy against breast cancer.
“…PLGA is successfully used in the research of drug delivery systems, because of its biodegradability and low systemic toxicity, it has also been approved by the US Food and Drug Administration (FDA) for medical applications. [8][9][10][11] PLGA can be formulated as PNP using several different methods, such as emulsiīcationevaporation, nanoprecipitation or solvent displacement, solvent diffusion, and phase-inversion; with sizes ranging from 10 to 1000 nm. 12,13 When encapsulating hydrophobic compounds, two of the most commonly used techniques are the emulsiīcation-solvent evaporation technique and the nanoprecipitation technique.…”
This study presents the influence of the primary formulation parameters on the formation of poly-dl-lactic-co-glycolic nanoparticles by the emulsification-solvent evaporation, and the nanoprecipitation techniques.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citationsācitations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.